The Promise of ESCAT: A New System for Evaluating Cancer Drug-Target Pairs

The authors evaluate the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), praising it as a useful common language for classifying the evidence behind target-drug combinations in precision oncology, while identifying areas for improvement to increase its utility for clinical decision-making, trial planning, and reimbursement policy.